Telomir Pharmaceuticals Announces Significant Reduction of Oxidative Stress in Human Retinal Cell Lines, Advancing Potential Treatment for Age-Related Macular Degeneration (AMD)
Telomir Pharmaceuticals (NASDAQ:TELO) has announced breakthrough results from preclinical studies of Telomir-1 in human retinal cell lines, showing significant reduction of copper and iron-induced Reactive Oxygen Species (ROS). The studies demonstrate potential treatment for Age-Related Macular Degeneration (AMD), a leading cause of blindness in adults over 50.
The research revealed that Telomir-1 effectively reduced ROS levels at low concentrations, suggesting regulatory properties rather than chelation effects. This indicates promising therapeutic potential for AMD treatment. The compound targets oxidative stress and metal-induced toxicity, key factors in AMD progression, offering a novel approach compared to current treatments that mainly manage symptoms.
The company plans to conduct AMD disease models to evaluate Telomir-1's efficacy in vivo, while also expanding research into other conditions including Wilson's disease, progeria, cancer, Alzheimer's, and infectious diseases.
Telomir Pharmaceuticals (NASDAQ:TELO) ha annunciato risultati straordinari da studi preclinici su Telomir-1 in linee cellulari retiniche umane, mostrando una significativa riduzione delle specie reattive dell'ossigeno (ROS) indotte da rame e ferro. Gli studi dimostrano un potenziale trattamento per la Degenerazione Maculare Legata all'Età (AMD), una delle principali cause di cecità negli adulti sopra i 50 anni.
La ricerca ha rivelato che Telomir-1 riduce efficacemente i livelli di ROS a basse concentrazioni, suggerendo proprietà regolatorie piuttosto che effetti di chelazione. Questo indica un promettente potenziale terapeutico per il trattamento dell'AMD. Il composto mira allo stress ossidativo e alla tossicità indotta dai metalli, fattori chiave nella progressione dell'AMD, offrendo un approccio innovativo rispetto ai trattamenti attuali che gestiscono principalmente i sintomi.
L'azienda prevede di condurre modelli di malattia AMD per valutare l'efficacia di Telomir-1 in vivo, espandendo anche la ricerca su altre condizioni, tra cui la malattia di Wilson, la progeria, il cancro, l'Alzheimer e le malattie infettive.
Telomir Pharmaceuticals (NASDAQ:TELO) ha anunciado resultados innovadores de estudios preclínicos de Telomir-1 en líneas celulares retinianas humanas, mostrando una reducción significativa de las especies reactivas de oxígeno (ROS) inducidas por cobre y hierro. Los estudios demuestran un tratamiento potencial para la Degeneración Macular Relacionada con la Edad (AMD), una de las principales causas de ceguera en adultos mayores de 50 años.
La investigación reveló que Telomir-1 reduce efectivamente los niveles de ROS a bajas concentraciones, sugiriendo propiedades regulatorias en lugar de efectos de quelación. Esto indica un prometedor potencial terapéutico para el tratamiento de la AMD. El compuesto se dirige al estrés oxidativo y a la toxicidad inducida por metales, factores clave en la progresión de la AMD, ofreciendo un enfoque novedoso en comparación con los tratamientos actuales que principalmente manejan los síntomas.
La compañía planea llevar a cabo modelos de enfermedad de AMD para evaluar la eficacia de Telomir-1 in vivo, mientras también amplía la investigación en otras condiciones, incluyendo la enfermedad de Wilson, la progeria, el cáncer, el Alzheimer y las enfermedades infecciosas.
텔로미르 제약 (NASDAQ:TELO)은 인간 망막 세포주에서 텔로미르-1의 전임상 연구 결과가 획기적임을 발표하며, 구리와 철에 의해 유도된 반응성 산소 종(ROS)의 상당한 감소를 보여주었습니다. 이 연구는 노인성 황반변성(AMD)에 대한 잠재적인 치료법을 입증하며, 이는 50세 이상의 성인에서 실명의 주요 원인 중 하나입니다.
연구 결과 텔로미르-1이 낮은 농도에서 ROS 수준을 효과적으로 감소시킨다는 것이 밝혀졌으며, 이는 킬레이션 효과보다는 조절 특성을 시사합니다. 이는 AMD 치료를 위한 유망한 치료 잠재력을 나타냅니다. 이 화합물은 산화 스트레스와 금속 유도 독성에 초점을 맞추며, 이는 AMD 진행의 주요 요인으로, 현재의 치료법이 주로 증상 관리에 집중하는 것과 비교하여 새로운 접근 방식을 제공합니다.
회사는 텔로미르-1의 효능을 평가하기 위해 AMD 질병 모델을 수행할 계획이며, 윌슨병, 프로제리아, 암, 알츠하이머 및 감염병을 포함한 다른 질환에 대한 연구도 확대할 예정입니다.
Telomir Pharmaceuticals (NASDAQ:TELO) a annoncé des résultats révolutionnaires issus d'études précliniques sur Telomir-1 dans des lignées cellulaires rétiniennes humaines, montrant une réduction significative des espèces réactives de l'oxygène (ROS) induites par le cuivre et le fer. Les études démontrent un traitement potentiel pour la Dégénérescence Maculaire Liée à l'Âge (AMD), une des principales causes de cécité chez les adultes de plus de 50 ans.
La recherche a révélé que Telomir-1 réduisait efficacement les niveaux de ROS à faibles concentrations, suggérant des propriétés régulatrices plutôt que des effets de chélation. Cela indique un potentiel thérapeutique prometteur pour le traitement de l'AMD. Le composé cible le stress oxydatif et la toxicité induite par les métaux, des facteurs clés dans la progression de l'AMD, offrant une approche novatrice par rapport aux traitements actuels qui gèrent principalement les symptômes.
La société prévoit de mener des modèles de maladie AMD pour évaluer l'efficacité de Telomir-1 in vivo, tout en élargissant également la recherche sur d'autres conditions, y compris la maladie de Wilson, la progeria, le cancer, la maladie d'Alzheimer et les maladies infectieuses.
Telomir Pharmaceuticals (NASDAQ:TELO) hat bahnbrechende Ergebnisse aus vorklinischen Studien zu Telomir-1 in menschlichen Netzhautzelllinien bekannt gegeben, die eine signifikante Reduzierung von kupfer- und eiseninduzierten reaktiven Sauerstoffspezies (ROS) zeigen. Die Studien zeigen ein potenzielles Behandlung für altersbedingte Makuladegeneration (AMD), eine der führenden Ursachen für Blindheit bei Erwachsenen über 50 Jahren.
Die Forschung hat gezeigt, dass Telomir-1 die ROS-Werte bei niedrigen Konzentrationen effektiv reduziert, was auf regulatorische Eigenschaften anstatt auf Chelationseffekte hinweist. Dies deutet auf ein vielversprechendes therapeutisches Potenzial für die Behandlung von AMD hin. Die Verbindung zielt auf oxidativen Stress und metallinduzierte Toxizität ab, die Schlüsselfaktoren im Fortschreiten von AMD sind, und bietet einen neuartigen Ansatz im Vergleich zu aktuellen Behandlungen, die hauptsächlich Symptome behandeln.
Das Unternehmen plant, AMD-Krankheitsmodelle durchzuführen, um die Wirksamkeit von Telomir-1 in vivo zu bewerten, während es auch die Forschung zu anderen Erkrankungen wie Wilson-Krankheit, Progerie, Krebs, Alzheimer und Infektionskrankheiten ausweitet.
- Successful preclinical results showing significant reduction of oxidative stress in human retinal cells
- Telomir-1 demonstrated effectiveness at low concentrations, indicating high therapeutic potential
- Novel approach targeting root causes rather than symptoms, potentially offering better treatment options
- Still in preclinical stage, requiring further studies and clinical trials before potential commercialization
- No concrete timeline provided for clinical development
- Multiple competing treatment approaches already exist in the market
Insights
The preclinical results for Telomir-1 represent a potentially significant advancement in AMD treatment, targeting a $7.7 billion global market with substantial growth potential. The current standard of care, primarily anti-VEGF injections, generates over
The scientific approach is particularly noteworthy for three reasons:
- Telomir-1's ability to reduce ROS levels through regulatory mechanisms rather than chelation suggests a more sophisticated and potentially safer therapeutic approach
- The compound's effectiveness at low concentrations indicates favorable drug-like properties, important for clinical development
- The mechanism of action could have broader applications beyond AMD, potentially addressing multiple age-related conditions
However, several critical factors warrant careful consideration:
- The path from preclinical success to FDA approval is lengthy and complex, typically requiring 7-10 years and investments exceeding
$1 billion - Success in human retinal cell lines, while promising, doesn't guarantee efficacy in animal models or human trials
- Competition in the AMD space is intense, with several major pharmaceutical companies developing novel treatments
The planned expansion into other indications like Wilson's disease, progeria, and Alzheimer's suggests a platform technology strategy that could significantly enhance Telomir's value proposition. However, this early-stage company will need substantial capital to advance multiple programs simultaneously, likely necessitating either strategic partnerships or significant additional funding rounds.
MIAMI, FLORIDA / ACCESS Newswire / February 18, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or Telomir, a leader in age-reversal science, today announced groundbreaking results from its recent preclinical studies conducted in human retinal cell lines. These studies demonstrated the ability of Telomir-1 to significantly reverse copper and iron-induced elevation of Reactive Oxygen Species (ROS).
Age-Related Macular Degeneration (AMD) and Current Treatment Challenges
AMD is a leading cause of blindness in adults over 50, affecting millions worldwide. The disease is characterized by the progressive deterioration of the retinal pigment epithelium (RPE) and photoreceptor cells, leading to central vision loss. AMD is classified into two forms:
Dry (atrophic) AMD, the most common form, which is characterized by a gradual loss of RPE and photoreceptors due to oxidative stress and inflammation.
Wet (neovascular) AMD, a more severe form, where abnormal blood vessel growth causes rapid and severe vision loss.
Current treatments primarily aim to slow the progression of AMD rather than reverse the damage. Anti-VEGF injections, the standard for wet AMD, can reduce vision loss but require frequent and costly treatments with potential risks such as retinal detachment and infection. The AREDS2 formula, an antioxidant supplement, offers modest benefits in delaying intermediate AMD but does not restore lost vision. Laser and photodynamic therapies, once widely used, are now less common due to risks of retinal scarring and limited long-term efficacy. While gene and stem cell therapies are emerging, no FDA-approved treatments directly target oxidative stress, a key factor in AMD progression.
Despite these treatments, there remains an urgent need for therapies that address the root causes of AMD, particularly oxidative stress and metal-induced toxicity, which drive retinal degeneration. Telomir-1 represents a novel approach by targeting these underlying mechanisms, offering a potential disease-modifying solution rather than just slowing its effects.
"The continued success of Telomir-1 in regulating oxidative stress is further proof of its potential to transform healthcare and redefine how we approach aging and age-related diseases," said Erez Aminov, Chairman & CEO of Telomir. "Rather than merely addressing symptoms, our focus is on targeting the root causes of disease at the cellular level. Telomir-1's ability to mitigate oxidative damage underscores its promise as a breakthrough therapy, not only for AMD but for a broader range of age-related conditions."
Telomir-1: A Novel Approach to Combating Oxidative Stress in AMD
Telomir's lead compound, Telomir-1, was developed to neutralize metal-induced oxidative stress-a key driver of AMD progression. In a recently conducted preclinical study using human retinal cell lines, Telomir-1 demonstrated the ability to significantly reduce ROS levels, thereby reversing oxidative damage, suggesting therapeutic potential in AMD and other retinal diseases.
Key Study Findings:
Copper and iron exposure significantly increased ROS levels in human retinal cells, accelerating oxidative stress and cellular damage.
Telomir-1 treatment resulted in a significant reduction of copper and iron-induced ROS elevation, mitigating oxidative stress at the cellular level.
Telomir-1 exhibited strong ROS reduction properties at low concentrations, suggesting regulatory, rather than chelation properties, and a high therapeutic potential for AMD.
The ability to reduce oxidative stress may have implications beyond AMD, potentially benefiting other retinal diseases linked to oxidative damage.
"Our findings reinforce the crucial role of metal ions and oxidative stress in AMD and suggest that Telomir-1 could provide a breakthrough approach to protecting retinal cells from degeneration," said Dr. Angel, Chief Scientific Advisor at Telomir. "Unlike current AMD treatments that primarily manage symptoms, Telomir-1 directly targets oxidative stress and metal-induced toxicity, key factors in disease progression."
Next Steps in Telomir-1 Development
Telomir has planned AMD disease models to further evaluate the efficacy of Telomir-1 in vivo. These studies will explore how Telomir-1 can protect against progressive retinal degeneration and vision loss, paving the way for potential clinical development.
In addition to AMD, Telomir will be conducting studies to evaluate the potential of Telomir-1 in Wilson's disease, progeria, cancer, Alzheimer's, and other age-related conditions. Furthermore, research will be expanded into infectious diseases, including influenza and bird flu, to assess how Telomir-1's metal ion regulation capabilities may impact viral pathogenesis and immune response.
About Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is a pre-clinical stage pharmaceutical company seeking to lead development in several areas, including age-reversal science. Telomir is focused on the development of Telomir-1, a novel small molecule metal ion regulator designed to lengthen the DNA's protective telomere caps, which are crucial in the aging process. Telomir's goal is to explore the potential of Telomir-1, starting with ongoing research in animals and then in humans.
Telomeres are the protective end caps of a chromosome made up of DNA sequences and proteins. As humans age, telomeres shorten, with metal reactivity accelerating the process, which presents humans and pet animals with an increased chance of contracting a number of degenerative and age-related diseases. Telomir's goal is to develop and gain regulatory approval for Telomir-1, proposed to be dosed orally, with the broader aim of promoting longevity and enhancing overall quality of life.
Telomir-1 is in preclinical development and has not yet been tested in humans. There is no assurance that Telomir-1 will proceed through development or will ultimately receive FDA approval for marketing.
Cautionary Note Regarding Forward-Looking Statements
This press release, statements of Telomir Pharmaceuticals' management or advisors related thereto, and the statements contained in the news story linked in this release contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1.
Contact Information
Helga Moya
info@telomirpharma.com
(786) 396-6723
SOURCE: Telomir Pharmaceuticals, Inc
View the original press release on ACCESS Newswire
FAQ
What are the key findings of TELO's recent preclinical studies for AMD treatment?
How does Telomir-1's approach to AMD treatment differ from current treatments?
What are TELO's next development steps for Telomir-1?
What potential market does TELO's AMD treatment target?
